Nautilus shifted strategy after ongoing reagent challenges delayed proteome-scale ambitions. The company said it is redirecting most R&D resources toward a targeted protein assay market it views as a multi-billion-dollar opportunity, focusing on a narrower, more feasible route to adoption. The move reflects a common bioprocess and diagnostics reality: platform-wide scaling can be bottlenecked by consumables and assay reproducibility. By concentrating on targeted measurements, Nautilus is attempting to convert technical friction into a clearer product path. For the tools ecosystem, the shift may reshape competitive positioning around targeted vs. discovery proteomics workflows and shorten timelines to commercially viable offerings.